Login

Landos Biopharma, Inc. SEC Filings

Filed On Filing
03 Jun 2024 15-12G
23 May 2024 Form 4: Mayleben Timothy M, Director

Disposed of 3,600 Stock Option (right to buy) (Disposition to Issuer)

23 May 2024 Form 4: Girao Tiago, Director

Disposed of 5,400 Stock Option (right to buy) (Disposition to Issuer)

23 May 2024 Form 4: Callori Fred, Director

Disposed of 5,400 Stock Option (right to buy) (Disposition to Issuer)

23 May 2024 Form 4: Batycky Alka, Director

Disposed of 3,600 Stock Option (right to buy) (Disposition to Issuer)

23 May 2024 Form 4: Adsett Roger, Director

Disposed of 7,200 Stock Option (right to buy) (Disposition to Issuer)

23 May 2024 Form 4: Garabedian Christopher Nishan, Director

Disposed of 5,400 Stock Option (right to buy) (Disposition to Issuer)

23 May 2024 Form 4: Cataldi Fabio, Chief Medical Officer

Disposed of 48,813 Restricted Stock Unit (Disposition to Issuer) · Disposed of 58,448 Employee Stock Option (right to buy) (Disposition to Issuer)

23 May 2024 Form 4: Oakes Gregory, Director

Disposed of 54,454 Restricted Stock Unit (Disposition to Issuer) · Disposed of 215,253 Employee Stock Option (right to buy) (Disposition to Issuer)

23 May 2024 RW
23 May 2024 S-8 POS
23 May 2024 S-8 POS
23 May 2024 S-8 POS
23 May 2024 S-8 POS
23 May 2024 25-NSE
23 May 2024 8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +5 more
23 May 2024 8-K: Submission of Matters to a Vote of Security Holders
09 May 2024 10-Q
25 Apr 2024 DEFM14A
16 Apr 2024 10-K/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support